Speaker(s): 

Clara Bishay, PharmD Resident I, Pharmacy, Geisinger Staff - has nothing to disclose  

Moderator(s): 

Sarah Hale, Pharm.D., BCPPS. Director of Pharmacy, Geisinger-has nothing to disclose 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Explain why dual antiplatelet therapy (DAPT) is used post percutaneous coronary intervention in myocardial infarction and the risks associated with prolonged aspirin use. 
• Summarize the design, patient population, and key findings of the TARGET-FIRST and NEO-MINDSET trials
• Analyze the implications of study findings on current guidelines, patient care, and future directions. 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brain Simpkins, PharmD, Jessica Milheim, CPhT, and Tiffany Tang, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None